Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Glaucoma, Open-Angle, Glaucoma
Interventions: iStent Inject Implantation; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Phoenix, Arizona • Torrance, California • Dallas, Texas

Conditions: Keratoconus, Glaucoma
Interventions: Ophthalmodynamometer, Goldmann applanation tonometer, Pentacam, ORA, Optical Coherence Tomography (OCT); Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma
Interventions: Micropulse Transscleral Cyclophotocoagulation; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 20 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate; Drug
Lead sponsor: Sylentis, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Artesia, California • Petaluma, California • Morrow, Georgia + 1 more

Conditions: Ocular Hypertension, Glaucoma
Interventions: latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1999
U.S. locations: 53
States / cities: Anaheim, California • Sacramento, California • San Francisco, California + 39 more

Conditions: Primary Open Angle Glaucoma
Interventions: AMDX-2011P; Drug
Lead sponsor: Amydis Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Phoenix, Arizona • Glendale, California • Newport Beach, California

Conditions: Glaucoma
Interventions: SENSIMED Triggerfish; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma, Glaucoma, Suspect
Interventions: Standard GAT, Fixed force GAT, Upright applanating prototype, Pneumotonometer; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma
Interventions: Ahmed FP7 Valve, Baerveldt-350 Tube; Device
Lead sponsor: Credit Valley EyeCare; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 3
States / cities: Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin

Conditions: Retinal Disease, Healthy, Glaucoma, Corneal Diseases
Interventions: OCT; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 22 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Anaheim, California • West Hartford, Connecticut • Wellesley Hills, Massachusetts + 1 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Wenatchee, Washington

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Travoprost 0.004%; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neovascular Glaucoma
Interventions: Aflibercept; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 90 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, AMD, Diabetic Retinopathy (DR)
Interventions: Chronic Disease Intervention CDI; Other
Lead sponsor: Interstat LLC; Other
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Glaucoma
Interventions: FDT visual field, Standard HVF; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Glaucoma, Open Angle or Ocular Hypertension
Interventions: brinzolamide 1% ophthalmic suspension, Azopt 1%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Ocular Hypertension, Glaucoma
Interventions: AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, AGN-210669 vehicle ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Artesia, California

Conditions: Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1976 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma and Ocular Hypertension
Interventions: Low Energy SLT, Standard Energy SLT; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 28
States / cities: Laguna Hills, California • Pasadena, California • Sacramento, California + 22 more

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas

Conditions: Open Angle Glaucoma
Interventions: Travoprost; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 13
States / cities: Hemet, California • Petaluma, California • Fort Collins, Colorado + 10 more

Conditions: Glaucoma, Cataract
Interventions: Cornea/Anterior Segment OCT CASIA2, Optovue RTVue XR Avanti; Device
Lead sponsor: Tomey Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Glaucoma, Glaucoma Following Surgery
Interventions: Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering); Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glaucoma
Interventions: Ranibizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

iStent Inject New Enrollment Post-Approval Study

Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus

How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?

SYL040012, Treatment for Open Angle Glaucoma

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

SENSIMED Triggerfish Safety and Tolerability

Automated Applanation Tonometry - Updated

The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma

Data Gathering for A10900

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases

Frequency Doubling Technology (FDT) Mobile Visual Field Testing

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Pigment Dispersion Syndrome With and Without Glaucoma

Clarifying the Optimal Application of SLT Therapy Trial

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Study of Exchange of Travoprost Intraocular Implant

Comparative Study of the Cornea/Anterior Segment OCT CASIA2 and the RTVue XR OCT Avanti With AngioVue Software

Anterior-segment OCT (AS-OCT) and Intraoperative OCT (iOCT) for Trans- Conjunctival Needle Revision (TCNR)

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery